Lupus Erythematosus Systemic clinical trials

Explore recruiting lupus erythematosus systemic clinical trials.

Recruiting lupus erythematosus systemic studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lupus Erythematosus Systemic trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

(Synbiose-2 )Synergetic B-cell immunomodulation in SLE – 2 nd study

Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus

France, Spain, Poland, Italy

Phase II and Phase III (Integrated) EU CTIS Study details

A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus

Romania, Hungary, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Systemic Lupus Erythematosus

Spain, Poland, Denmark, Bulgaria, Portugal, Italy +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE-1, FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO­-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, FOOD EFFECT, AND DRUG-DRUG INTERACTION OF ORALLY ADMINISTERED VENT-03 IN HEALTHY VOLUNTEERS

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A clinical study of MK-1045 in people with lupus or rheumatoid arthritis (MK-1045-004)

Italy, Belgium, Romania

Human Pharmacology (Phase I)- Other EU CTIS Study details

Lupus Erythematosus Systemic trials by city

Lupus Erythematosus Systemic in Toronto Lupus Erythematosus Systemic in Vancouver Lupus Erythematosus Systemic in Montreal Lupus Erythematosus Systemic in Calgary Lupus Erythematosus Systemic in Edmonton Lupus Erythematosus Systemic in Ottawa Lupus Erythematosus Systemic in Winnipeg Lupus Erythematosus Systemic in Quebec City Lupus Erythematosus Systemic in Hamilton Lupus Erythematosus Systemic in Kitchener Lupus Erythematosus Systemic in London Lupus Erythematosus Systemic in Halifax Lupus Erythematosus Systemic in New York Lupus Erythematosus Systemic in Los Angeles Lupus Erythematosus Systemic in Chicago Lupus Erythematosus Systemic in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease